Latest Biotech News

Revolution Medicines presented additional details from its Phase 3 pancreatic cancer study featuring daraxonrasib at ASCO, with investigators describing results as “landscape-changing.” In the...

Revolution Medicines began shipping daraxonrasib to physicians and patients under an early access program authorized by the FDA, CEO Mark Goldsmith said during an ASCO-linked briefing. The therapy...

Akeso and Summit reported overall survival results showing their PD-1/VEGF bispecific ivonescimab plus chemotherapy reduced the risk of death by 34% versus PD-1 inhibitor plus chemo in previously...

Eli Lilly licensed Hanmi Pharm’s Phase 2-stage GLP-2 agonist sonefpeglutide for short bowel syndrome, expanding Lilly’s gastrointestinal pipeline. Under the agreement, Lilly will pay $75 million...

The FDA granted Fast Track designation to Autobahn Therapeutics’ elunetirom (ABX-002) for adjunctive treatment of depressive episodes associated with bipolar I or bipolar II disorder in adults....

Puxitatug samrotecan (AZD8205) produced high response rates in B7-H4-expressing recurrent or progressive endometrial cancer in the Phase 1/2a BLUESTAR study, supporting an FDA Breakthrough Therapy...

Signos secured $20 million to expand its glucose monitoring platform beyond diabetes and into weight loss. The approach combines Dexcom’s over-the-counter CGM offering with a software app that...

Evaluate’s orphan drugs report projects that orphan drugs will account for more than 21% of all prescription pharmaceutical sales by 2032, up from 15% in 2022. The analysis also forecasts rare...

Replimune moved to a third attempt for RP1 in advanced melanoma after the FDA’s rejection history and recent leadership turnover at the agency. The company said it will resubmit its biologics...

Revolution Medicines’ daraxonrasib delivered broadly strong survival and disease-control results in metastatic pancreatic cancer, with detailed interim data presented at ASCO. In the Phase 3 trial...

Akeso’s ivonescimab extended survival in squamous non-small cell lung cancer in a China-only Phase 3 program presented at ASCO. In Harmoni-6, the PD-1/VEGF bispecific plus chemotherapy reduced the...

AstraZeneca/az’s pipeline ADC candidate puxitatug samrotecan generated high response rates in B7-H4–selected endometrial cancer data shown at ASCO. In the Phase 1/2a BLUESTAR study (NCT05123482),...

Giredestrant, an oral selective estrogen receptor degrader (SERD), reduced recurrence risk across menopausal subgroups in ER+/HER2− early breast cancer in the lidERA Phase 3 trial results...

Autobahn Therapeutics received FDA Fast Track designation for elunetirom (ABX-002) as adjunctive treatment for bipolar depression. The company said the designation is intended to increase the...

Pfizer agreed to pay upfront and milestones totaling as much as $10.5 billion for a multi-asset oncology collaboration with Innovent Biologics. The deal sets Pfizer up for a 12-candidate antibody...

Signos raised $20 million to expand its glucose monitoring platform beyond diabetes into weight-loss applications. The company’s system pairs Dexcom’s over-the-counter CGM devices with an app that...

Chan Zuckerberg Initiative’s Biohub unveiled an AI-generated protein atlas, the ESM Atlas, expanding predicted protein structure coverage by more than a billion entries. Biohub said the database,...

BMG LABTECH highlighted how microplate readers and reporter assays support real-time microbiology workflows in pathogen studies at the University of Glasgow. In a discussion with microbiologist...

Revolution Medicines disclosed expanded Phase 3 results for daraxonrasib in patients with KRAS-mutant metastatic pancreatic cancer, reporting a median overall survival gain of 13.2 months across...

Akeso and Summit Therapeutics’ ivonescimab posted a statistically significant overall survival improvement versus a PD-1 inhibitor plus chemotherapy in Harmoni-6, a Phase 3 trial run entirely in...